Sign in

    Jeremiah Lorentz

    Research Analyst at BofA Securities

    Jeremiah Lorentz is an Equity Research Analyst at BofA Securities, specializing in healthcare sector coverage with a focus on biopharmaceutical and therapeutics companies. He has been involved in research coverage for companies such as Pharvaris N.V. and Fulcrum Therapeutics, playing a key role in introducing and analyzing these firms at major healthcare investment conferences. Lorentz began his career after earning an undergraduate degree from Washington University in St. Louis and holds a research analyst position at BofA, with previous background data indicating a solid tenure in equity research. He maintains professional credentials suitable for a research analyst role at a leading Wall Street firm, though specific FINRA registrations or license numbers are not publicly listed.

    Jeremiah Lorentz's questions to Fulcrum Therapeutics (FULC) leadership

    Jeremiah Lorentz's questions to Fulcrum Therapeutics (FULC) leadership • Q4 2024

    Question

    Jeremiah Lorentz, on behalf of BofA Securities, asked about the key takeaways from the upcoming FSHD data presentation and whether Fulcrum would consider a follow-on program. He also inquired about the operating expense outlook for 2025.

    Answer

    CEO Alexander Sapir explained that while the losmapimod drug performed as expected in the FSHD trial, a high placebo response meant the study missed its endpoint, and Fulcrum will not pursue it further, instead focusing on hematology. CFO Alan Musso stated that restructuring is complete and guided for a 2025 cash burn of $55 million to $65 million.

    Ask Fintool Equity Research AI